Tumor M2-PK: Difference between revisions

Revision as of 11:56, 9 February 2025

Tumor M2-PK

Diagram of glycolysis showing the role of M2-PK

Tumor M2-PK (also known as Tumor M2 Pyruvate Kinase) is an isoform of the enzyme pyruvate kinase that is expressed in proliferating cells, such as cancer cells. It plays a crucial role in the altered metabolism of cancer cells, often referred to as the Warburg effect.

Function

Tumor M2-PK is a key enzyme in the final step of glycolysis, where it catalyzes the conversion of phosphoenolpyruvate (PEP) to pyruvate, generating adenosine triphosphate (ATP) in the process. Unlike the other isoforms of pyruvate kinase, Tumor M2-PK can exist in two different forms: a highly active tetrameric form and a less active dimeric form. The dimeric form is predominant in tumor cells and is associated with the accumulation of glycolytic intermediates that are used for biosynthetic processes, supporting rapid cell growth and division.

Clinical Significance

Tumor M2-PK is considered a potential biomarker for cancer diagnosis and monitoring. Elevated levels of Tumor M2-PK have been detected in the blood and stool of patients with various types of cancer, including colorectal cancer, lung cancer, and breast cancer. The measurement of Tumor M2-PK levels can aid in the early detection of cancer and in assessing the effectiveness of treatment.

Research and Applications

Research into Tumor M2-PK has led to the development of diagnostic tests that measure its levels in biological samples. These tests are used in conjunction with other diagnostic methods to improve the accuracy of cancer detection. Additionally, Tumor M2-PK is being studied as a potential target for cancer therapy, with the aim of disrupting the altered metabolic pathways in cancer cells.

Related pages

References

@@ Line 1: / Line 1: @@
-'''Translational Medicine''' is a rapidly growing discipline in biomedical research and aims to expedite the discovery of new diagnostic tools and treatments by using a multi-disciplinary, highly collaborative, "bench-to-bedside" approach.
+== Tumor M2-PK ==
-== Overview ==
+[[File:M2-PKglycolysiseng.png|thumb|right|Diagram of glycolysis showing the role of M2-PK]]
-Within the [[public health]] context, the goal of translational medicine is to combine disciplines, resources, expertise, and techniques within these pillars to promote enhancements in prevention, diagnosis, and therapies. Accordingly, the [[National Institutes of Health]] (NIH) has made a significant investment in translational medicine, particularly through its Clinical and Translational Science Award (CTSA) program.
+'''Tumor M2-PK''' (also known as Tumor M2 Pyruvate Kinase) is an isoform of the enzyme [[pyruvate kinase]] that is expressed in proliferating cells, such as [[cancer]] cells. It plays a crucial role in the altered metabolism of cancer cells, often referred to as the [[Warburg effect]].
-== Bench to Bedside ==
+== Function ==
+Tumor M2-PK is a key enzyme in the final step of [[glycolysis]], where it catalyzes the conversion of [[phosphoenolpyruvate]] (PEP) to [[pyruvate]], generating [[adenosine triphosphate]] (ATP) in the process. Unlike the other isoforms of pyruvate kinase, Tumor M2-PK can exist in two different forms: a highly active tetrameric form and a less active dimeric form. The dimeric form is predominant in tumor cells and is associated with the accumulation of glycolytic intermediates that are used for biosynthetic processes, supporting rapid cell growth and division.
-The concept of "bench to bedside" is a way of conveying the notion of translational medicine. The idea is that basic science research at the "bench" leads to findings that can be developed into clinical applications for patients at the "bedside". This process often involves animal models or human clinical trials.
+== Clinical Significance ==
+Tumor M2-PK is considered a potential [[biomarker]] for cancer diagnosis and monitoring. Elevated levels of Tumor M2-PK have been detected in the blood and stool of patients with various types of cancer, including [[colorectal cancer]], [[lung cancer]], and [[breast cancer]]. The measurement of Tumor M2-PK levels can aid in the early detection of cancer and in assessing the effectiveness of treatment.
-== Clinical and Translational Science Award (CTSA) ==
+== Research and Applications ==
+Research into Tumor M2-PK has led to the development of diagnostic tests that measure its levels in biological samples. These tests are used in conjunction with other diagnostic methods to improve the accuracy of cancer detection. Additionally, Tumor M2-PK is being studied as a potential target for cancer therapy, with the aim of disrupting the altered metabolic pathways in cancer cells.
-The [[Clinical and Translational Science Award]] (CTSA) program is a consortium led by the National Institutes of Health's National Center for Advancing Translational Sciences (NCATS). The CTSA program aims to improve human health by streamlining science, transforming training environments, and improving the conduct, quality, and dissemination of clinical and translational research.
+== Related pages ==
+* [[Glycolysis]]
+* [[Warburg effect]]
+* [[Cancer biomarker]]
+* [[Pyruvate kinase]]
-== Challenges ==
+== References ==
+{{Reflist}}
-Despite the promise of translational medicine, there are significant challenges to its full implementation. These include the need for more and better collaboration between basic scientists and clinicians, the need for more funding, and the need for better training and education in translational medicine.
+[[Category:Enzymes]]
+[[Category:Cancer biomarkers]]
-== See Also ==
-* [[Clinical Research]]
-* [[Public Health]]
-* [[National Institutes of Health]]
-* [[Clinical and Translational Science Award]]
-[[Category:Medicine]]
-[[Category:Biomedical Research]]
-[[Category:Public Health]]
-{{stub}}